Collaborative Community Against Coronavirus CIC
Registered name: COLLABORATIVE COMMUNITY AGAINST CORONAVIRUS CIC
Collaborative Community Against Coronavirus CIC made £786k revenue and £29.9k profit in the year to 31 Mar 2025.
Collaborative Community Against Coronavirus CIC’s revenue grew 144% to £786k in the year to 31 Mar 2025, with £29.9k profit and 0 employees. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 6 yrs · since 2020
- Type
- Community Interest Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Mar 2022 | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 |
|---|---|---|---|---|
| Disclosure | No P&L | Full P&L | Full P&L | Full P&L |
| Profit & loss | ||||
| Revenue (turnover) | — | £226k | £322k | £786k |
| Cost of sales | — | £24.3k | £45.9k | £756k |
| Gross profit | — | £202k | £276k | £30.1k |
| Operating profit | — | £0 | £0 | £0 |
| Profit before tax | — | £0 | £0 | £36.9k |
| Profit after tax | — | £0 | £0 | £29.9k |
| Profit (best available) | — | £0 | £0 | £29.9k |
| Employees (average) | 0 | 0 | 0 | 0 |
| Ratios | ||||
| Profit margin | — | 0% | 0% | 3.8% |
| Gross margin | — | 89.3% | 85.7% | 3.8% |
| Growth (year on year) | ||||
| Revenue growth | — | — | ▲42.6% | ▲144.2% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £230k | £1.3m | £1.3m | £575k |
| Net assets | £216k | £216k | £216k | £246k |
| Current assets | £232k | £1.3m | £1.4m | £687k |
| Debtors | £1.3k | £1.4k | £46.2k | £112k |
| Deferred income | — | — | £1.2m | £433k |
| Source | FullAccounts · bulk data Mar 2024 | FullAccounts · bulk data Mar 2024 | FullAccounts · bulk data Jan 2025 | FullAccounts · bulk data Dec 2025 |
How the business works
- Profit margin
- 3.8%
- Profit ÷ revenue.
- Gross margin
- 3.8%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- —
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 55.1%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 14.2%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▲14%
- Now £246k
- Cash at bank
- ▼57%
- Now £575k
- Headcount
- —
- Now 0
- Deferred income
- ▼63%
- Now £433k
- Fixed assets
- —
- Now —
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Similar profitable businesses
- Nuritas UK LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £88.8k
- Staff
- 4
- Adorx Therapeutics LimitedEdinburgh · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £211k
- Staff
- 0
- Clinicology Ltd.Guildford · Research and experimental development on biotechnology
- Revenue
- £1.4m
- Profit
- £79.1k
- Staff
- 7
Sources
Latest figures from FullAccounts for the year to 31 Mar 2025 (profit £29.9k), from the Companies House accounts bulk data published Dec 2025. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.